Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia by Bristar Immunotech Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia is under clinical development by...
Data Insights
Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia by China Immunotech (Beijing) Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia is under clinical development by...